Skip to Content

Evotec SE ADR

EVO: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$8.40XxcJmzbxfnnd

Positive Outlook on Evotec's Growth Thanks to CDMO Outsourcing Trends and Investment in the Pipeline

Business Strategy and Outlook

Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on collaboration with clients. The firm offers services across a variety of therapeutic areas and serves a diverse client base of large and midsize pharmaceutical and biotechnology companies. Following a recent period of investment that has weighed on returns, Evotec appears well positioned to mature and stabilize its business as its strategic growth initiatives materialize.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of EVO so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center